Related references
Note: Only part of the references are listed.Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials
Alexander H. Seeto et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Prognostic Value of Abdominal Aortic Calcification: A Systematic Review and Meta-Analysis of Observational Studies
Kevin Leow et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
Cy Fixen et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial
Ian R. Reid et al.
CALCIFIED TISSUE INTERNATIONAL (2021)
Abdominal aortic calcification is associated with a higher risk of injurious fall-related hospitalizations in older Australian women
Abadi K. Gebre et al.
ATHEROSCLEROSIS (2021)
Cardiovascular Safety and Sclerostin Inhibition
Bente Lomholt Langdahl et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Role of coronary artery calcium score in the primary prevention of cardiovascular disease
Khurram Nasir et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
A Single-Center Prospective Study of 116 Women with Osteoporosis Treated with Zoledronic Acid Monitored by Electrocardiography for the Development of Cardiac Arrhythmia During the Acute Phase in China
HuaFeng Zhuang et al.
MEDICAL SCIENCE MONITOR (2021)
Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study
Kristin M. D'Silva et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study
Cristiana Cipriani et al.
ENDOCRINE (2021)
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Ian R. Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
Fang Lv et al.
BONE (2020)
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
Katrine Hass Rubin et al.
BONE (2020)
No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis
Laurence Ferrieres et al.
ARCHIVES OF OSTEOPOROSIS (2020)
Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
G. Cai et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
S. R. Cummings et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
N. R. Fuggle et al.
DRUGS (2020)
Nitrogen-Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture
Chor-Wing Sing et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density
Alexander J. Rodriguez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Jonas Bovijn et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan
W. -J. Hong et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria
Patrizio Lancellotti et al.
JAMA CARDIOLOGY (2019)
Association Between Abdominal Aortic Calcification, Bone Mineral Density, and Fracture in Older Women
Joshua R. Lewis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis
Steven R. Cummings et al.
JAMA INTERNAL MEDICINE (2019)
Bisphosphonates and lower mortality risk: when it sounds to be good to be true horizontal ellipsis
W. D. Leslie
OSTEOPOROSIS INTERNATIONAL (2019)
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
Michael R. McClung et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Exploring the Links Between Common Diseases of AgeingOsteoporosis, Sarcopenia and Vascular Calcification
Alexander J. Rodriguez et al.
CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM (2019)
Long-Term Atherosclerotic Vascular Disease Risk and Prognosis in Elderly Women With Abdominal Aortic Calcification on Lateral Spine Images Captured During Bone Density Testing: A Prospective Study
Joshua R. Lewis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
The Emperor's New Clothes: What Randomized Controlled Trials Don't Cover
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Piet Geusens et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis
Smriti Murali Krishna et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Arterial calcification: A new perspective?
R. Nicoll et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Atrial fibrillation and risk of hip fracture: A population-based analysis of 113,600 individuals
Christopher X. Wong et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study
Nam-Kyong Choi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Bone Mineral Density and Risk of Heart Failure in Older Adults: The Cardiovascular Health Study
Raymond B. Fohtung et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Guido Kranenburg et al.
ATHEROSCLEROSIS (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis
Smita Jha et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
Dae Hyun Kim et al.
PLOS ONE (2015)
Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
Abhishek Sharma et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
Elizabeth J. Samelson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
Robert F. Storey et al.
PLATELETS (2014)
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials
E. Barrett-Connor et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials
E. M. Lewiecki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Bisphosphonates and Atrial Fibrillation Systematic Review and Meta-Analysis
Yoon Kong Loke et al.
DRUG SAFETY (2009)
Cardiovascular Diseases and Risk of Hip Fracture
Ulf Sennerby et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Increased Bone Resorption Is Associated With Increased Risk of Cardiovascular Events in Men: The MINOS Study
Pawel Szulc et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Atrial fibrillation in fracture patients treated with oral bisphosphonates
B. Abrahamsen et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Alendronate affects calcium dynamics in cardiomyocytes in vitro
Naomi Kemeny-Suss et al.
VASCULAR PHARMACOLOGY (2009)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cardiovascular diseases and future risk of hip fracture in women
U. Sennerby et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Alendronate and atrial fibrillation
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relationship between osteoporosis and cardiovascular disease in postmenopausal women
LB Tankó et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins
RE Hewitt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Metacarpal cortical area and risk of coronary heart disease - The Framingham Study
EJ Samelson et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Inflammation as a risk factor for atrial fibrillation
RJ Aviles et al.
CIRCULATION (2003)
The natural history of sclerosteosis
H Hamersma et al.
CLINICAL GENETICS (2003)
Diagnosis of osteoporosis and assessment of fracture risk
JA Kanis
LANCET (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
